[go: up one dir, main page]

PT946157E - Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular - Google Patents

Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular

Info

Publication number
PT946157E
PT946157E PT97954571T PT97954571T PT946157E PT 946157 E PT946157 E PT 946157E PT 97954571 T PT97954571 T PT 97954571T PT 97954571 T PT97954571 T PT 97954571T PT 946157 E PT946157 E PT 946157E
Authority
PT
Portugal
Prior art keywords
treatment
topical use
kapa
opioid agonists
ocular pain
Prior art date
Application number
PT97954571T
Other languages
English (en)
Inventor
Daniel A Gamache
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of PT946157E publication Critical patent/PT946157E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97954571T 1996-12-16 1997-12-11 Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular PT946157E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3290996P 1996-12-16 1996-12-16

Publications (1)

Publication Number Publication Date
PT946157E true PT946157E (pt) 2002-07-31

Family

ID=21867521

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97954571T PT946157E (pt) 1996-12-16 1997-12-11 Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular

Country Status (11)

Country Link
US (1) US6191126B1 (pt)
EP (1) EP0946157B1 (pt)
JP (2) JP2001506652A (pt)
AT (1) ATE214272T1 (pt)
AU (1) AU731447B2 (pt)
CA (1) CA2275167C (pt)
DE (1) DE69711078T2 (pt)
DK (1) DK0946157T3 (pt)
ES (1) ES2174337T3 (pt)
PT (1) PT946157E (pt)
WO (1) WO1998026770A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214272T1 (de) 1996-12-16 2002-03-15 Alcon Lab Inc Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
AU1828399A (en) * 1997-12-22 1999-07-12 Alza Corporation Novel formulations for the transdermal administration of asimadoline
BR9912827A (pt) 1998-07-16 2001-05-02 Sloan Kettering Inst Cancer Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
AU5170400A (en) 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AU2001257326A1 (en) 2000-04-28 2001-11-12 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
MX346312B (es) 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
FR3044227B1 (fr) * 2015-11-30 2017-11-24 Pharmaleads Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
EP3932390A1 (en) * 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2632520B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Derives de la phenothiazine analgesiques
US4939135A (en) 1988-10-03 1990-07-03 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5360611A (en) 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
FR2646773B1 (fr) 1989-05-12 1994-05-13 Chauvin Sa Laboratoire Composition pharmaceutique a base de paracetamol
JPH06122677A (ja) 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5688955A (en) 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
ATE214272T1 (de) 1996-12-16 2002-03-15 Alcon Lab Inc Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz

Also Published As

Publication number Publication date
ES2174337T3 (es) 2002-11-01
JP2009067806A (ja) 2009-04-02
WO1998026770A2 (en) 1998-06-25
CA2275167C (en) 2008-10-28
AU731447B2 (en) 2001-03-29
AU5898798A (en) 1998-07-15
DK0946157T3 (da) 2002-07-08
EP0946157A2 (en) 1999-10-06
WO1998026770A3 (en) 1998-09-03
DE69711078D1 (de) 2002-04-18
DE69711078T2 (de) 2002-10-02
ATE214272T1 (de) 2002-03-15
EP0946157B1 (en) 2002-03-13
US6191126B1 (en) 2001-02-20
CA2275167A1 (en) 1998-06-25
HK1020867A1 (en) 2000-05-26
JP2001506652A (ja) 2001-05-22

Similar Documents

Publication Publication Date Title
PT946157E (pt) Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
BR0008323A (pt) Derivado de gabapentina para a prevenção e o tratamento de dor visceral
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
PT1414473E (pt) Composicoes de administracao oral para o tratamento de disturbios do couro cabeludo
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
MX9601149A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
BR0214060A (pt) Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
NO990450L (no) Behandling av sinnslidelser
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението